Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2026-01-05 @ 1:07 AM
Study NCT ID:
NCT06469203
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-08-13
First Post:
2024-06-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Oxytocin Effectiveness in First Trimester Dilatation and Curettage
Sponsor:
Assuta Ashdod Hospital
Organization:
Study Overview
Official Title:
Oxytocin Effectiveness in First Trimester Dilatation and Curettage
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to investigate the impact of oxytocin on perioperative blood loss during the D\&C procedure, as well as to assess early and late complications associated with it's use.
Detailed Description:
Study Design
This study is a prospective randomized placebo-controlled double-blind trial. Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.
Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
The medication bags will be prepared by the Assuta Ashdod University Hospital Pharmacy, coded with serial numbers, and randomized using computerized software. Both the investigators and patients will remain unaware of the composition of the distension medium to ensure blinding.
A total of 160 patients will be included in the sample size resulting in a net total of 80 patients per group as described below. Patients who choose to withdraw from the study will still be analyzed as intention-to-treat patients.
Inclusion Criteria:
All patients admitted to the OBGYN Assuta Ashdod Hospital for elective surgical termination of pregnancy due to missed miscarriages in the first trimester, with gestational age range of 6.0 to 11.6 weeks.
Patients aged 18 years and older who are capable to provide informed consent.
Exclusion criteria
* individual intolerance to oxytocin
* mullerian anomalies
* Fibroid uterus
* thrombophilia or coagulation disorders
* cardiovascular disease
Primary outcome
Perioperative Blood Loss Assessment:
We will assess perioperative blood loss by:
* Measuring the content collected in the vacuum apparatus after the procedure.
* Recording hemoglobin and hematocrit levels prior to the procedure.
* Measuring hemoglobin and hematocrit levels immediately after the procedure.
* Monitoring hemoglobin and hematocrit levels two weeks post-procedure.
Secondary outcomes
-perioperative complications according to the Dindo-Clavien scale
This study is a prospective randomized placebo-controlled double-blind trial. Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.
Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
The medication bags will be prepared by the Assuta Ashdod University Hospital Pharmacy, coded with serial numbers, and randomized using computerized software. Both the investigators and patients will remain unaware of the composition of the distension medium to ensure blinding.
A total of 160 patients will be included in the sample size resulting in a net total of 80 patients per group as described below. Patients who choose to withdraw from the study will still be analyzed as intention-to-treat patients.
Inclusion Criteria:
All patients admitted to the OBGYN Assuta Ashdod Hospital for elective surgical termination of pregnancy due to missed miscarriages in the first trimester, with gestational age range of 6.0 to 11.6 weeks.
Patients aged 18 years and older who are capable to provide informed consent.
Exclusion criteria
* individual intolerance to oxytocin
* mullerian anomalies
* Fibroid uterus
* thrombophilia or coagulation disorders
* cardiovascular disease
Primary outcome
Perioperative Blood Loss Assessment:
We will assess perioperative blood loss by:
* Measuring the content collected in the vacuum apparatus after the procedure.
* Recording hemoglobin and hematocrit levels prior to the procedure.
* Measuring hemoglobin and hematocrit levels immediately after the procedure.
* Monitoring hemoglobin and hematocrit levels two weeks post-procedure.
Secondary outcomes
-perioperative complications according to the Dindo-Clavien scale
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: